Raphael Pharmaceutical Inc.
Raphael Pharmaceutical Inc. (RAPH): 5 pipeline candidates · ~0 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
0.1 months
0% dilution
Lead: Phase 1
5 candidates
N/A
N/A
A transparent, data-derived signal for Raphael Pharmaceutical Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$28.2M
Cash
$1K
Quarterly Burn
$44K
Runway
0.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| cannabis-based | Preclinical |
| cbd-x | Preclinical |
| covid-19 product candidate | Preclinical |
| ra product candidate | Preclinical |
| raphael's formula | Phase 1 |
Frequently asked questions
How many drug candidates are in Raphael Pharmaceutical Inc.'s pipeline?
Raphael Pharmaceutical Inc. (RAPH) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Raphael Pharmaceutical Inc.'s lead drug candidate?
Raphael Pharmaceutical Inc.'s most advanced tracked candidate is cannabis-based (Preclinical) for Asthma.
What is Raphael Pharmaceutical Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Raphael Pharmaceutical Inc. has approximately 0.1 months of cash runway.
What is Raphael Pharmaceutical Inc.'s market capitalization?
Raphael Pharmaceutical Inc.'s market capitalization is approximately $28.2M.
Who is the CEO of Raphael Pharmaceutical Inc.?
Mr. Shlomo Pilo is the chief executive officer of Raphael Pharmaceutical Inc. (RAPH).
Get the full picture on Raphael Pharmaceutical Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.